ND Expert Sean Kassen: Statement on first FDA-approved treatment for Niemann-Pick Type C disease
September 20, 2024
September 20, 2024
NOTRE DAME, Indiana, Sept. 20 -- The University of Notre Dame issued the following news:
Sean Kassen, director of the Ara Parseghian Medical Research Fund at Notre Dame. (Photo by Barbara Johnston/University of Notre Dame)
Today, the FDA announced the first approved treatment for Niemann-Pick Type C (NPC) disease: an oral medication named Miplyffa (arimoclomol). Sean Kassen, director of the Ara Parseghian Medical Research Fund at the University of Notre Dame, said this . . .
Sean Kassen, director of the Ara Parseghian Medical Research Fund at Notre Dame. (Photo by Barbara Johnston/University of Notre Dame)
Today, the FDA announced the first approved treatment for Niemann-Pick Type C (NPC) disease: an oral medication named Miplyffa (arimoclomol). Sean Kassen, director of the Ara Parseghian Medical Research Fund at the University of Notre Dame, said this . . .